These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36156450)

  • 1. The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression.
    Kim CM; Lee JB; Shin SJ; Ahn JB; Lee M; Kim HS
    ESMO Open; 2022 Oct; 7(5):100577. PubMed ID: 36156450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-Analysis.
    Ciccarese C; Iacovelli R; Bria E; Palazzo A; Maiorano BA; Mosillo C; Carbone C; Piro G; Tortora G
    J Immunother; 2020 Apr; 43(3):95-103. PubMed ID: 32080018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis.
    Nishijima TF; Muss HB; Shachar SS; Moschos SJ
    Cancer Treat Rev; 2016 Apr; 45():30-7. PubMed ID: 26946217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors in advanced cutaneous melanoma: a systematic review and meta-analysis of efficacy and review of characteristics.
    Mahdiabadi S; Momtazmanesh S; Karimi A; Rezaei N
    Expert Rev Anticancer Ther; 2023; 23(12):1281-1293. PubMed ID: 37908134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are immune checkpoint inhibitors ineffective in treating patients with head and neck squamous cell carcinoma aged 75 years or Older? A Meta-Analysis.
    Zhang S; Zheng M; Tian H; Liu W; Feng Z; Xing S; Han F
    Oral Oncol; 2024 Jan; 148():106632. PubMed ID: 38039875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
    Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
    Front Oncol; 2022; 12():753234. PubMed ID: 35280736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
    Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
    Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
    Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
    Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
    Raphael J; Batra A; Boldt G; Shah PS; Blanchette P; Rodrigues G; Vincent MD
    Clin Lung Cancer; 2020 Mar; 21(2):106-113.e5. PubMed ID: 31992521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
    J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
    Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
    JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between patients' age and cancer immunotherapy efficacy.
    Wu Q; Wang Q; Tang X; Xu R; Zhang L; Chen X; Xue Q; Wang Z; Shi R; Wang F; Ju F; Zhang B; Zhou YL
    Oncoimmunology; 2019; 8(4):e1568810. PubMed ID: 30906662
    [No Abstract]   [Full Text] [Related]  

  • 14. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis.
    Yang M; Wang Y; Yuan M; Tao M; Kong C; Li H; Tong J; Zhu H; Yan X
    Int Immunopharmacol; 2020 Nov; 88():106876. PubMed ID: 32799113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
    Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
    Front Immunol; 2022; 13():968729. PubMed ID: 35967438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis.
    Li P; Yang X; Feng Y; Wu L; Ma W; Ding G; Wei Y; Sun L
    Onco Targets Ther; 2018; 11():7521-7527. PubMed ID: 30464500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Yan X; Tian X; Wu Z; Han W
    Front Oncol; 2020; 10():1671. PubMed ID: 33072551
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluating the Efficacy of Immune Checkpoint Inhibitors in Elderly Patients: A Systematic Review and Meta-analysis.
    Kim HS
    Methods Mol Biol; 2025; 2857():117-125. PubMed ID: 39348060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.